Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 25 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLobllwUUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> MVyyOVk3ODJ6Mh?=
KellyCis83 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\MXmlEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= M3HuSVI2QTZyMkiy
SK-N-AS NE\BNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PNcGlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= NYTHS|hHOjV7NkCyPFI>
SK-N-ASCis24 MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LwTmlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= NVvhc21HOjV7NkCyPFI>
U87 NUHITFlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEewOWcxNTVyIN88US=> MoP1OFghcA>? NX;WW3Bp\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDzbYxq[mmwaX6= NUjtSZo5OjV5NUCyO|M>
HCT116 NFi1VZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LUWlAvPS1{LkWg{txO MojjOFjDqGkEoB?= NF\uR2xKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= MV[yOVc1Pjd4Mx?=
HT-29 NY\5cZM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDONE42NTJwNTFOwG0> NHTHPYk1QMLiaNMg MkTvTWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? MUeyOVc1Pjd4Mx?=
Caco2 NVu1OFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvINE42NTJwNTFOwG0> MXG0POKhcMLi MlPjTWM2OD15LkK2xsDDucLiMT62POKh|ryP M3PmSVI2PzR4N{[z
COLO 205 M4Dzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP0NE42NTJwNTFOwG0> Ml3vOFjDqGkEoB?= MX\JR|UxRTFwNkJCpOKyyqByLkCyxsDPxE1? M1nMVlI2PzR4N{[z
SW480 M3X1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLUOXJGOC53LUKuOUDPxE1? MnrEOFjDqGkEoB?= NF\kR25KSzVyPUSuPVLDqMLzwrCwMlM{yqEQvF2= M1j6PVI2PzR4N{[z
HEK293T Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrqXGJsOS13IN88US=> NYTTdIxmPDkEoHlCpC=> NFfoZoNKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= M3POXlI2PzR4N{[z
Hep3B  MoTZSpVv[3Srb36gRZN{[Xl? NXPINXZXOTBizszN M{\jRlQ5yqCqwrC= NELDXFBz\WS3Y3XzJJRp\SCnbnjhcoNqdmdiZX\m[YN1KG:oIFLNVE03 M{XLSlI2PjN|NU[0
Hep3B  M{nUcGZ2dmO2aX;uJGF{e2G7 MmHiNE4yNTFyIN88US=> MXiyOEBp NWHIUod[e3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B Mn75NlU3OzN3NkS=
HEK293 NIfUcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4raNWlEPTB;Nz6xOOKhyrIEoECuN|bDqM7:TR?= NUX0fVNjOjV4MEOxNlI>
DU145 NWLVW4JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPLNGVKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= NWq4fHdJOjV4MEOxNlI>
HCT15 M2[x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? MnTyNlU3ODNzMkK=
T47D MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3wbIlZUUN3ME2zMlE5yqEEsdMgNE4yOcLizszN MWKyOVYxOzF{Mh?=
SMMC-7721 NGHhdlFHfW6ldHnvckBCe3OjeR?= NFjNWo81OCEQvF2= M17SRlQ5KGh? NYPyUHpbTE2VTx?= NXf4SWRXcW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? MUWyOVU1PDN4MR?=
MDA-MB-231 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYm3NuKhcA>? MkKzTWM2OD1{MT6yxsDDucLiND6yxsDPxE1? NHLaOWwzPTR6NkKxPS=>
MCF-7 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[3NuKhcA>? MnP1TWM2OD1zMD65xsDDucLiMj6xxsDPxE1? MWOyOVQ5PjJzOR?=
Jurkat NYPvOoViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;hO|LDqGh? MnnPTWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? M4X6WFI2PDh4MkG5
HeLa Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e2XlczyqCq NHq0PW5KSzVyPUOuPeKhyrIEoEKuN:Kh|ryP MXOyOVQ5PjJzOR?=
MCF7  NVTq[4dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HPR|UuOTByIN88US=> M3;wflch\A>? MoTTbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGSw[24zPTR5Mk[xPS=>
K562 NEe2eWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfyO|LDqGh? M1TYfmlEPTB;MD6yPeKh|ryP M2Sy[|I2Ojh{NkWz
K/VP.5 NV;qPHluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rtRlczyqCq NVXkToZKUUN3ME20MlnDqM7:TR?= NFfEeYszPTJ6Mk[1Ny=>
SH-EP  NH7hRZhHfW6ldHnvckBCe3OjeR?= NXrsWFBLOjEEoN88[{9udA>? NG[xR4MzPMLiaB?= MoXUbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= NIq4TlMzPTJ4MUm4NS=>
SCC25 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjN[YdrOjUEoHi= M3vNOGlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= MoH5NlUzOjB5Mkm=
CAL27 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f6T|I1yqCq MlSyTWM2OD13Mj6xxsDDucLiMT6wPeKh|ryP NX\oUY5iOjV{MkC3Nlk>
FaDu NWi4ZZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X3eVI1yqCq M2LRTmlEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= NHTXNmYzPTJ{MEeyPS=>
SCC25 M1jHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK0POKhcA>? M3K4cGlEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= M3\vZ|I2OjJyN{K5
CAL27 M1LabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jZSFQ5yqCq NIXpPHZKSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN NXzZRXdIOjV{MkC3Nlk>
FaDu M3rSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPvZ2JmPDkEoHi= NH7YOpZKSzVyPU[uOFPDqMLzwrCxMlE{yqEQvF2= M2rwNVI2OjJyN{K5
SCC25 M{\CfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13hR|czyqCq MXTJR|UxRThwNEJCpOKyyqBzLkGxxsDPxE1? NUTlRmsyOjV{MkC3Nlk>
CAL27 NFLJ[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PjflczyqCq NX\NU2I4UUN3ME20MlI4yqEEsdMgNU4yPMLizszN M4e2WVI2OjJyN{K5
FaDu M4XDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;EO|LDqGh? NVHNVmF3UUN3ME21MlAzyqEEsdMgNU4yPcLizszN MVmyOVIzODd{OR?=
MCF-7 NHu4TZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3OOFjDqGkEoB?= MoLOSG1UVw>? MnPtTWM2OD15LkNCpOKyyqByLklCpO69VQ>? NF3wbGYzPTJzNkO3PC=>
T-47D NX;UNpUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKyUIZkPDkEoHlCpC=> MWPEUXNQ NFLMeppKSzVyPUeuO:KhyrIEoECuO:Kh|ryP M3noO|I2OjF4M{e4
MDA-MB-231 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnQ[JQ1QMLiaNMg MmnpSG1UVw>? NUi4dJh4UUN3ME2xNk45yqEEsdMgNU4xyqEQvF2= M3zEVlI2OjF4M{e4
DU145 MXPBdI9xfG:|aYOgRZN{[Xl? M1vQTVExNTFyMDFOwG0> MVi4JIg> MYjEUXNQ NHSybolqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= MVyyOVE1QTZ6MR?=
DU145 stem-like MmDJRZBweHSxc3nzJGF{e2G7 NHXIZ2gyOC1zMECg{txO M4L4UVghcA>? M{jtXmROW09? NIPoTIVqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWCyOVE1QTZ6MR?=
DU145 MWXGeY5kfGmxbjDBd5NigQ>? NYHiOIZOOTBvMUCwJO69VQ>? M{nF[lIhcA>? MmD5SG1UVw>? M4\XTolv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4XO[FI2OTR7Nkix
DU145 stem-like MXvGeY5kfGmxbjDBd5NigQ>? MUixNE0yODBizszN M{fjfVIhcA>? NHvnW3hFVVOR MYLpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MnWyNlUyPDl4OEG=
UW228-3 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[2SlAvODFvM{CwJO69VQ>? MVq0PEBp NHjlUW1FVVOR MlPaTWM2OD1yLkm5xsDPxE1? MUSyOVEyQTF6NR?=
NSCs MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYewMlAyNTNyMDFOwG0> NHrPeJM1QCCq NUDSWG03TE2VTx?= M{\6b2lEPTB;MD6zMVPDqM7:TR?= MV6yOVEyQTF6NR?=
MKL-1  MYPGeY5kfGmxbjDBd5NigQ>? M1PBN|ExNTFyMECgcm0> MoTFOEBl NULCdJdGcW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= MX2yOVEyPjd3NB?=
MCF7 EV MUnGeY5kfGmxbjDBd5NigQ>? NF7JXIkyOC1zMECg{txO NFe0cmkz6oDLaB?= MV\pcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> MYGyOVA5QDJyMx?=
MCF 7BMI1 Ml7KSpVv[3Srb36gRZN{[Xl? M13FU|ExNTFyMDFOwG0> NFXqeYcz6oDLaB?= Mk\BbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> NVu4W5d2OjVyOEiyNFM>
MCF7 EV M2jyRmZ2dmO2aX;uJGF{e2G7 NFvMdFMyOC1zMECg{txO NVLOdnl5OuLCiXi= MlmxSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u NIToRWszPTB6OEKwNy=>
MCF7 BMI1 MXXGeY5kfGmxbjDBd5NigQ>? NUfHNFdCOTBvMUCwJO69VQ>? NYDXRXRlOuLCiXi= NHPsZmlGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> M4jTXlI2ODh6MkCz
HepG2 M1j2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vYSmROW00EoB?= M4HsOmlEPTB;M{CuNVbDqMLzwrCwMlUxyqEQvF2= Mn\VNlUxPzh|MUG=
MOLT-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHmSG1UV8Li MYrJR|UxRTBwMEWxxsDDucLiMD6wNFLDqM7:TR?= M2[5Z|I2ODd6M{Gx
HT1080 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXhNU0yODBizszN NGn1dXk1NzJ2L{S4JIg> M33JOmROW00EoB?= NXX1WZp5cW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u NXnKWJl[OjVyN{iwOlQ>
HT1080 Mon3SpVv[3Srb36gRZN{[Xl? MojXNE4xODBzLUGwNEDPxE1? NFTpOFMyNTJ2IHi= MWTEUXNQyqB? Mmn3bY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MXKyOVA4QDB4NB?=
HT1080 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGwMlAxODFvMUCwJO69VQ>? MYCyOEBp M3HZPWROW00EoB?= M1zIOINifXOnczDhckBqdmO{ZXHz[UBqdiC2aHWgcpVu[mW{IH;mJINmdGy|IHnuJGczN01uIIfobYxmKGSnY4LlZZNqdmdiUzDhcoQhTzFicHjhd4Uh[2WubIO= NF3XZW8zPTB5OEC2OC=>
HD-MY-Z NH7RSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDCOWszPC92OD:3NkBp MlPyTWM2OO,:nkGwNEDPxE1? NGT6cWwzPTB2OEKzOi=>
DOHH-2 NGXJcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT6U3IzPCCq NH62b45KSzVy78{eNVAxKM7:TR?= NH\HfWozPTB2OEKzOi=>
DOHH-2 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH4[oo1QCCq NVzu[VJSUUN3ME2xPU46yqEQvF2= NXvRXIxKOjVyNEiyN|Y>
DOHH-2 MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnMO|IhcA>? NGnM[G1KSzVyPUZCpO69VQ>? M2nmbFI2ODR6MkO2
REH NH7PWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXOzNVg1OjRiaB?= M3XuXmlEPTB;MD6wNlfDqM7:TR?= NHjPT5kzPTB2OEKzOi=>
REH MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zFO|Q5KGh? Mk\1TWM2OD1yLkCxOOKh|ryP NX\0VG0{OjVyNEiyN|Y>
REH NEXwXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHtOW1GPzJiaB?= NGTidYJKSzVyPUCuNFE2yqEQvF2= NFKyOI0zPTB2OEKzOi=>
HH NXHGNpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn34NlQhcA>? NUTNZWxOUUN3ME2xNFQvP8LizszN MWCyOVA1QDJ|Nh?=
HH NGq2RndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7C[4ExPDhiaB?= M1vyWGlEPTB;NEiuOuKh|ryP NHXBcHYzPTB2OEKzOi=>
HH MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLvO|IhcA>? MoHiTWM2OD1zND63xsDPxE1? M3TEeFI2ODR6MkO2
HuT-78 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7UeVAzPCCq M4f3fWlEPTB;OT6zxsDPxE1? NEHLe4szPTB2OEKzOi=>
HuT-78 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17qSFQ5KGh? NFOzUYlKSzVyPUSuN:Kh|ryP M1;1bFI2ODR6MkO2
HuT-78 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTafVI{PzJiaB?= MVXJR|UxRTRwMtMg{txO M1f1XFI2ODR6MkO2
OPM-2 M4nSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:yOEBp MUnJR|UxRTJ2LkJCpO69VQ>? MnL2NlUxPDh{M{[=
OPM-2 M2\4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITsfWk1QCCq NU[wXmNjUUN3ME20xsDPxE1? NH3HcGozPTB2OEKzOi=>
OPM-2 M{LhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnETGN[PzJiaB?= MlfRTWM2OD1zLkRCpO69VQ>? MWWyOVA1QDJ|Nh?=
RPMI-8226 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnTfI4zPCCq Ml3NTWM2OD1zME[uOuKh|ryP MX2yOVA1QDJ|Nh?=
RPMI-8226 NF7QdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jNdlQ5KGh? NFzv[2FKSzVyPUmxMlHDqM7:TR?= Mo\GNlUxPDh{M{[=
RPMI-8226 NUDzOHU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXqbJo4OiCq MkKwTWM2OD1zND65xsDPxE1? NFz0WGgzPTB2OEKzOi=>
U-266 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPFT2xNOjRiaB?= MXfJR|UxRTh4LkNCpO69VQ>? NEjLbVUzPTB2OEKzOi=>
U-266 M1nuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn2b|BNPDhiaB?= NG\kfo1KSzVyPU[4MlTDqM7:TR?= M{G4ZlI2ODR6MkO2
U-266 NWTBZ45JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInU[oI4OiCq NYi5[nNVUUN3ME2yO{41yqEQvF2= MmHiNlUxPDh{M{[=
Kelly NYPWU3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnvNE0yOCEQvF2= MU[3NuKhcA>? MkDKTWM2OD1zLkWxPOKh|ryP MWWyOVAxQDlyMB?=
SH-SY5Y  NYq0cm5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCwMVExKM7:TR?= NGnjfHo4OsLiaB?= NYmzZXBzUUN3ME2wMlc2PMLizszNxsA> MYOyOVAxQDlyMB?=
SK-N-AS MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfINE0yOCEQvF2= MWS3NuKhcA>? NIfBeI5KSzVyPUGuO|EzyqEQvF5CpC=> M3voXFI2ODB6OUCw
SK-N-DZ M{XrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHtNE0yOCEQvF2= NHf4OpY4OsLiaB?= NUC0UFRVUUN3ME21MlQ5PcLizszN NYr2U3kzOjVyMEi5NFA>
HepG2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T1bFQ5yqCq Mm[1SG1UV8Li NGLlXHlKSzVyPUGzMlY2yqEEsdMgNE46OsLizszN NIrzUVkzPDl7NkGzOi=>
A549 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV60POKhcA>? NFfjdpNFVVORwrC= Mof1TWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= NWDVcGtmOjR7OU[xN|Y>
MCF7 M3[1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkeyOFjDqGh? NUnYe2xbTE2VT9Mg Mn7uTWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= NEfmPGIzPDl7NkGzOi=>
HL-60  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XwUFczyqCq M1\oS2lEPTB;MD6xNwKBjc7:TR?= MWqyOFk6OzBzNB?=
HL-60[R] M3nFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPONYk4OsLiaB?= MXrJR|UxRTNwMUNihKXPxE1? MWGyOFk6OzBzNB?=
MIAPACA NG\NTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPHTVUxRTFwMzFCtUAxNjB|IN88US=> NH35O3kzPDl3M{iyNS=>
MCF-7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfWS2k2OD1yLkK1JOKyKDBwMTFOwG0> MXWyOFk2Ozh{MR?=
HeLa MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzaOIJIUTVyPUCuOlQhyrFiMD60JO69VQ>? M4jD[|I1QTV|OEKx
MO59K  M3i1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO3JIQ> NYD3S5IyUUN3ME2wMlE46oDHzszN MVKyOFk2OzV4MR?=
MO59J Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\HdFch\A>? MW\JR|UxRTBwMfMAie69VQ>? NFexRXgzPDl3M{W2NS=>
ME 180 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTXPZE1QMLiaNMg M1\NUmlEPTB;OD65xsDDucLiMD6z5qCG|ryP M{PvZVI1QTV|MEK3
MCF-7 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnuWIc1QMLiaNMg MoraTWM2OD1{Mz65JOKyKDBwM,MAie69VQ>? Ml3ENlQ6PTNyMke=
HeLa NH3aPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHhOFjDqGkEoB?= MUTJR|UxRTRwN{GgxtEhOS524pEF{txO M2i5cVI1QTV|MEK3
MDA-MB-453 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f2ZlQ5yqCqwrC= MnvmTWM2OD1zMj61JOKyKDBwOEZihKXPxE1? NInjd4ozPDl3M{CyOy=>
MDA-MB-231 NIS2RVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fFN|Q5yqCqwrC= MWLJR|UxRTJ2LkKyJOKyKDJwOUVihKXPxE1? MV6yOFk2OzB{Nx?=
PC-3 M2W0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe4cmFoPDkEoHlCpC=> M4j5OGlEPTB;MUSuOEDDuSB|LkKz5qCG|ryP NYm3SoxoOjR7NUOwNlc>
HT-29 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWO0POKhcMLi MlvhTWM2OD1{MT60OUDDuSB|Lki35qCG|ryP MlLQNlQ6PTNyMke=
BGC-823 M4PncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXlbIM1QMLiaNMg M{\K[2lEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= M3\JdlI1Pzl|OEe3
HeLa NWjCSHNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTCOFjDqGkEoB?= MYHJR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= NFX2SmUzPDd7M{i3Oy=>
A549 M3HlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;BOFjDqGkEoB?= M2DEfmlEPTB;MUO5MlU1KMLzIEeuNFXjiIYQvF2= MoHWNlQ4QTN6N{e=
HK-2 MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vqPFQ5yqCqwrC= Mn3XTWM2OD17LkG3JOKyKDFwNUlihKXPxE1? NFfQVW0zPDd7M{i3Oy=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products0

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID